<DOC>
	<DOCNO>NCT01976650</DOCNO>
	<brief_summary>This study Post-Market Surveillance study Korea evaluate safety efficacy dexamethasone 700 ㎍ ( OZURDEX® ) intravitreal implant use treat Branch Retinal Vein Occlusion , Central Retinal Vein Occlusion , non-infectious uveitis affect posterior segment eye clinical practice .</brief_summary>
	<brief_title>Safety Efficacy Dexamethasone ( OZURDEX® ) Intravitreal Implant Korea</brief_title>
	<detailed_description />
	<mesh_term>Retinal Vein Occlusion</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Patients Branch Retinal Vein Occlusion , Central Retinal Vein Occlusion , noninfectious uveitis affect posterior segment eye treat ( OZURDEX® ) clinical practice . Patients eye infection Patients glaucoma .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>